CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 70 enrolled
Drug / intervention
Topical tranexamic acid +2 moredrug
Likely dose
rivaroxaban (10mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03328832
NCT03328832Phase 4Completed

Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty

Chang Gung Memorial Hospital·interventional·Posted Nov 1, 2017·Updated Aug 10, 2021

In Brief

A Phase 4 clinical trial evaluating Topical tranexamic acid, Floseal®, and 1 other intervention for Osteoarthritis, Knee. Completed, enrolled 70 participants across 1 site.

Detailed Summary

Our purpose of this study therefore is to conduct a prospective randomized controlled trial to investigate the blood-conservation effect of combined topical application of these two hemostatic agents in different time during surgery and the safety compared with single topical application of TKA in a primary TKA procedure

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedNov 1, 2017
Enrollment StartSep 12, 2017
Primary CompletionSep 30, 2018
Study CompletionDec 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.7 years ago

Interventions

Topical tranexamic aciddrug

Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule

Floseal®drug

Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)

rivaroxaban (10mg)drug

Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.